[PSA as a marker for prostate cancer progression]

Area of Science:

• Oncology
• Urology
• Medical Diagnostics

Context:

• Prostate cancer exhibits variable biology, necessitating precise monitoring.
• Prostate-specific antigen (PSA) levels are critical indicators of treatment efficacy and disease recurrence.
• Biochemical recurrence (BCR) definitions differ significantly based on the therapeutic strategy employed.

Purpose:

• To elucidate the varied definitions of biochemical recurrence (BCR) for prostate cancer across different treatment modalities.
• To highlight the significance of prostate-specific antigen (PSA) kinetics and nadir values in predicting disease progression.
• To underscore the complexities in assessing BCR, including phenomena like PSA bounce and post-chemotherapy surge.

Summary:

• PSA monitoring is essential for tracking prostate cancer, with BCR definitions varying post-prostatectomy, external beam therapy, brachytherapy, hormonal therapy, and chemotherapy.
• Prostate-specific antigen doubling time (PSADT) is a key predictor of disease progression, with specific thresholds indicating recurrence or need for intervention.
• Challenges in BCR assessment include the 'PSA bounce' and 'PSA surge post-chemotherapy' syndrome, complicating accurate interpretation of PSA trends.

Impact:

• Provides a clear framework for interpreting PSA dynamics in prostate cancer management.
• Facilitates standardized assessment of treatment response and recurrence across diverse clinical scenarios.
• Aids clinicians in making informed decisions regarding treatment adjustments and surveillance strategies for prostate cancer patients.